| Half-life | 25 hours |
| Tmax | 6 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 20 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | Active metabolite: nortriptyline. Strong anticholinergic burden; avoid in elderly and cardiac disease. |
Severity: Severe
Adverse Effects:
Anticholinergic effects (dry mouth, constipation, urinary retention), sedation, orthostatic hypotension, arrhythmia risk
Contraindications:
Immediately post-MI, severe cardiac conduction abnormalities, concomitant MAOI use
Precautions:
Start low dose; avoid in elderly (Beers criteria); monitor ECG in cardiac disease; taper gradually.